A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Diseases of the Lung
What is the purpose of this trial?
The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILD® (trial 1199.247).
- Ages18 years and older
- Trial withBoehringer Ingelheim Pharmaceuticals, Inc.
- Start Date03/26/2019
- End Date08/30/2022
- Last Updated07/23/2019
- Study HIC#2000025055